Results 181 to 190 of about 423,816 (314)

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

Phase IV clinical trials for the treatment of non-small cell lung carcinoma (NSCLC): A systemic review from 2020-2025. [PDF]

Saudi Med J
Kariri YA, Alqasmi MH, Alqahtani BS.
europepmc   +1 more source

GEFITINIB (IRESSA) IN THE TREATMENT OF BRAIN METASTASES FROM NON-SMALL CELL LUNG CARCINOMA

, 2015
Д. Р. Насхлеташвили, В. А. Горбунова, Bychkov Mb, A. Кh. Bekyashev, В. Б. Карахан, В. А. Алешин, D. M. Bеlоv, Е. А. Москвина   +7 more
openalex   +2 more sources

Regulating Tumor Metabolic Reprogramming with Biomimetic Co‐Delivery of Simvastatin and Kynureninase for Immunotherapy

Advanced Science, EarlyView.
After the intravenous injection of biomimetic and pH/ROS‐responsive PTSK@CRM, the nanoparticles can be accumulated in tumors and release Sim and KYNase to inhibit the tumor growth, regulate the metabolism of cholesterol and Kyn, and reverse the immunosuppressive tumor microenvironment.
Jiaxin Yin, Shengcai Yang, Zengguang Liu, Songchen Zhao, Siyu Sun, Ziling Liu, Quanshun Li   +6 more
wiley   +1 more source

Mid-ventilation PTV approach for stereotactic ablative body radiotherapy in stage I non-small-cell lung carcinoma: Implementation of a single-system workflow. [PDF]

Tech Innov Patient Support Radiat Oncol
Shields-Dowton K, Poder J, Yuen J, Schmidt L, Chin YS.   +4 more
europepmc   +1 more source

Classification of Non-small Cell Lung Carcinoma in Transthoracic Needle Specimens Using MicroRNA Expression Profiling

, 2011
Ambrogio Fassina, Rocco Cappellesso, Matteo Fassan   +2 more
openalex   +1 more source

Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy

Advanced Science, EarlyView.
Heterogeneous cancer‐associated fibroblasts orchestrate dual immune microenvironments in LAGC. Abstract The potential for immunotherapy in patients with locally advanced gastric cancer (LAGC) is recently confirmed. To report the 3‐year follow‐up data are aimed from a novel clinical trial. This is a prospective single‐arm phase II trial.
Yao Lin, Xiong Sun, Chengguo Li, Ming Yang, Ke Wu, Ke Liu, Anshu Li, Xiaoming Shuai, Kailin Cai, Zheng Wang, Guobin Wang, Peng Zhang, Jianfeng Shen, Kaixiong Tao, Yuping Yin   +14 more
wiley   +1 more source

Transformation to Neuroendocrine Phenotype in Non-Small-Cell Lung Carcinoma: A Literature Review. [PDF]

Int J Mol Sci
Hernández de Córdoba I, Mielgo-Rubio X, Cejas P, Palomar Ramos J, Garrido-Rubiales B, Falagán Martínez S, Rubio Romero G, Morales Parga M, Moll Taltavull L, Fernández González A, Casado Sáenz E, Sereno M.   +11 more
europepmc   +1 more source

HPD is an m6A Methyltransferase that Protects Colorectal Cancer Cells from Ferroptotic Cell Death by m6A Methylating SLC7A11/GPX4

Advanced Science, EarlyView.
This study reveals that the tyrosine metabolic enzyme HPD functions as a previously uncharacterized, METTL3‐independent m6A methyltransferase. It promotes colorectal tumor progression by coordinately regulating the SLC7A11/GPX4 axis to suppress ferroptosis.
Jiyan Wang, Xintong Dai, Huanle Liu, Saiwei Hua, Hongkai Chang, Huanran Sun, Mingming Sun, Huifang Zhao, Kemin Ni, Fei Xie, Yaya Qiao, Qingle Gao, Chenxi Yu, Qijun Zhang, Jianshuang Guo, Chunze Zhang, Shuai Zhang, Changliang Shan   +17 more
wiley   +1 more source

PARP inhibition increases sensitivity to cisplatin in non-small-cell lung carcinoma via the induction of TET-dependent hydroxymethylation. [PDF]

Front Cell Dev Biol
Grdović N, Tolić A, Jovanović M, Rajić J, Đorđević M, Stojanović M, Hadžić SM, Marković T, Sarić A, Dinić S, Arambašić Jovanović J, Mihailović M, Podolski-Renić A, Pešić M, Vidaković M, Uskoković A.   +15 more
europepmc   +1 more source